KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.95

Biosimilar Versus Originator Pegfilgrastim for Preventing Chemotherapy-Induced Neutropenia: A Phase III Randomized, Multicenter, Evaluator-Blinded, Noninferiority Study.

Ruben D Kowalyszyn, Luis E Fein, Martin E Richardet, Mirta S Varela, Eduardo Ortiz, Cristian Micheri, Juan J Zarba, Susana Kahl, Ezequiel Klimovsky, Andrea A Federico, Jorge H Cassini, Gustavo Cortese, Nestor Lago

JCO Glob Oncol 8 e2100276

PMID35324270
PMCIDPMC9071253
DOI10.1200/GO.21.00276
发表日期2022-03-24
入排依据:The study is a randomized, Phase III trial with a drug intervention (biosimilar vs. originator pegfilgrastim) in oncology, but its primary efficacy endpoint is the duration of severe neutropenia (DSN), a continuous outcome, not a time-to-event endpoint. The secondary endpoints are also incidence-based or categorical measures (e.g., incidence of severe neutropenia, febrile neutropenia, infections) and are not reported as time-to-event analyses. Therefore, it does not meet the criterion of having a primary or key secondary time-to-event efficacy endpoint.
摘要

摘要

PURPOSE: This study evaluated the efficacy, safety, and immunogenicity of biosimilar pegfilgrastim (PegFilBS) and originator pegfilgrastim (PegFilOR) in patients with stage 2-4 breast cancer. METHODS: This phase III randomized, multicenter, evaluator-blinded, noninferiority study recruited women with stage 2-4 breast cancer in Argentina who were scheduled to receive chemotherapy. Stratification was based on the breast cancer stage. The primary end point was the duration of severe neutropenia (DSN, noninferiority margin: 1 day) in the first chemotherapy cycle. Secondary end points assessed were incidence of severe neutropenia, grade 3 neutropenia, febrile neutropenia, infections, postchemotherapy hospitalization and duration, and the incidence of adverse drug reactions (ADRs). RESULTS: A total of 120 patients were randomly assigned to receive PegFilBS (58 patients) or PegFilOR (62 patients). Severe neutropenia occurred in 52 of 283 cycles (18.4%) for 27 patients who received PegFilBS and in 48 of 297 cycles (16.2%) for 20 patients who received PegFilOR (P = .48). During the first cycle, severe neutropenia occurred in 16 patients who received PegFilBS (DSN: 0.78 ± 1.53 days) and in 11 patients who received PegFilOR (DSN: 0.53 ± 1.25 days; 95% CI, -0.26 to 0.76 days). In the intention-to-treat analysis, the mean DSN values were 0.90 ± 1.79 days for the PegFilBS group and 0.50 ± 1.21 for the PegFilOR group (95% CI, -0.15 to 0.95 days). No significant differences were observed for the secondary efficacy end points. Three patients experienced seven ADRs in the PegFilBS group while 10 patients experienced 31 ADRs in the PegFilOR group. The most common ADR was myalgia. CONCLUSION: Relative to PegFilOR, PegFilBS provided noninferior efficacy outcomes in Argentinian women with stage 2-4 breast cancer who were treated using myelosuppressive chemotherapy.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。